Study of RAD001 in Advanced Cholangiocarcinoma: RADiChol

• Status: Unknown status
• Trial end date: 2012-03-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a clinical trial investigating the effectiveness and safety of the study drug RAD001 in patients with advanced (metastatic) cholangiocarcinoma. Palliative chemotherapy provides some benefit to this group of patients. However, chemotherapy treatment only shows low rates of radiological response and short times to tumour progression. Therefore, further treatment options are urgently required.

In laboratory studies, RAD001 has been shown to interrupt the signals that cancer cells use to grow, spread and form new blood vessels (angiogenesis). RAD001 has been approved for the treatment of kidney cancer. It has also been approved for use in Australia for the treatment of patients with kidney and liver transplants, and has been used in thousands of patients worldwide for this indication. Preliminary studies suggest that RAD001 may have activity in a range of other cancers. This study will evaluate the activity of RAD001 in advanced cholangiocarcinoma.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Austin Health
• Treatments: Everolimus; Sirolimus

Criteria

Inclusion Criteria:

1. Histologically/cytologically confirmed adenocarcinoma of gall bladder, intra or extra-hepatic biliary tract

2. Metastatic or locally advanced (unresectable) disease

3. Adequate organ function; creatinine<1.5xULN, BR<1.5xULN Neut>1.5, Pts>100

4. WHO Performance status 0-2

5. No prior chemotherapy for advanced Cholangiocarcinoma (Prior adjuvant chemotherapy is accepted)

6. Measurable or non-measurable disease

7. Informed consent for study participation and donation of tumour tissue for evaluation of relevant translational endpoints

Exclusion Criteria:

1. Cytotoxic chemotherapy or immunotherapy within 4 weeks prior to enrolment

2. Prior therapy with mTOR inhibitors (sirolimus, temsirolimus, everolimus)

3. Known intolerance or hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus)

4. Uncontrolled diabetes mellitus or hyperlipidaemia

5. Patients who have any severe and/or uncontrolled medical conditions

6. Active or uncontrolled severe infection

7. Cirrhosis, chronic active hepatitis or chronic persistent hepatitis

8. Severely impaired lung function

9. Patients with a known history of HIV seropositivity

10. Patients who have a history of another primary malignancy (Exceptions include non-melanoma skin cancer, carcinoma in situ of uterine cervix, or any other cancer treated with curative intent without evidence of relapse for more than 2 years)

11. Female patients who are pregnant or nursing (lactating), or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes